UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics

UroGen Pharma Ltd. - Ordinary Shares (URGN): $8.39

-0.34 (-3.89%)

POWR Rating

Component Grades













Add URGN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where URGN ranks best; there it ranks ahead of 75.37% of US stocks.
  • URGN's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • URGN ranks lowest in Momentum; there it ranks in the 4th percentile.

URGN Stock Summary

  • UROGEN PHARMA LTD's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.94% of US listed stocks.
  • URGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 3.19% of US stocks.
  • With a year-over-year growth in debt of 11,868.51%, UROGEN PHARMA LTD's debt growth rate surpasses 99.65% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to UROGEN PHARMA LTD are ARDX, EMKR, DZSI, MRIN, and WISA.
  • URGN's SEC filings can be seen here. And to visit UROGEN PHARMA LTD's official web site, go to www.urogen.com.

URGN Valuation Summary

  • In comparison to the median Healthcare stock, URGN's price/sales ratio is 40% higher, now standing at 2.8.
  • Over the past 68 months, URGN's price/sales ratio has gone down 7.6.

Below are key valuation metrics over time for URGN.

Stock Date P/S P/B P/E EV/EBIT
URGN 2022-11-25 2.8 -2.8 -1.6 -2.2
URGN 2022-11-23 2.8 -2.8 -1.6 -2.2
URGN 2022-11-22 2.8 -2.8 -1.6 -2.2
URGN 2022-11-21 2.9 -2.8 -1.6 -2.2
URGN 2022-11-18 3.1 -3.1 -1.8 -2.3
URGN 2022-11-17 2.9 -2.9 -1.7 -2.2

URGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • URGN has a Quality Grade of D, ranking ahead of 11.82% of graded US stocks.
  • URGN's asset turnover comes in at 0.249 -- ranking 178th of 682 Pharmaceutical Products stocks.
  • BIIB, TECH, and ZGNX are the stocks whose asset turnover ratios are most correlated with URGN.

The table below shows URGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.249 0.897 -1.677
2021-03-31 0.148 0.901 -1.535
2020-12-31 0.080 0.914 -1.308
2020-09-30 0.023 0.907 -1.202
2020-06-30 0.002 0.871 -1.036
2020-03-31 0.000 1.000 -0.926

URGN Price Target

For more insight on analysts targets of URGN, see our URGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $42.60 Average Broker Recommendation 1.33 (Strong Buy)

URGN Stock Price Chart Interactive Chart >

Price chart for URGN

URGN Price/Volume Stats

Current price $8.39 52-week high $12.63
Prev. close $8.73 52-week low $4.85
Day low $8.20 Volume 45,200
Day high $8.93 Avg. volume 119,175
50-day MA $9.84 Dividend yield N/A
200-day MA $8.14 Market Cap 190.80M

UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.

URGN Latest News Stream

Event/Time News Detail
Loading, please wait...

URGN Latest Social Stream

Loading social stream, please wait...

View Full URGN Social Stream

Latest URGN News From Around the Web

Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference

PRINCETON, N.J., November 21, 2022--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a virtual fireside chat at the upcoming Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022 at 3:55 PM ET.

Yahoo | November 21, 2022

Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Estimates

Today is shaping up negative for UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders, with the analysts delivering a...

Yahoo | November 16, 2022

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma

PRINCETON, N.J., November 14, 2022--UroGen Highlights New Real-World Safety Data from a Retrospective Study Published in The British Journal of Urology International

Yahoo | November 14, 2022

UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

UroGen Pharma ( NASDAQ:URGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$16.1m (up 42% from 3Q 2021...

Yahoo | November 12, 2022

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Read More 'URGN' Stories Here

URGN Price Returns

1-mo -28.29%
3-mo 10.69%
6-mo 35.54%
1-year -26.98%
3-year -73.09%
5-year -79.25%
YTD -11.78%
2021 -47.23%
2020 -46.00%
2019 -22.50%
2018 15.72%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8026 seconds.